TNMG Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.75
- P/S (TTM)
- 0.03
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -164.6%
- Operating margin
- -25.9%
- Revenue growth YoY
- 5.7%
- Dividend yield
- —
- Beta
- 0.78
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About TNL Mediagene Ordinary Shares
Company profileTNL Mediagene Ordinary Shares is a forward-thinking biopharmaceutical company dedicated to innovating and commercializing advanced therapies for oncology and autoimmune diseases. With a robust pipeline enriched by state-of-the-art technologies and strategic partnerships, the company is well-positioned for substantial growth in the dynamic healthcare landscape. TNL Mediagene’s unwavering focus on scientific rigor and patient-centric solutions underscores its commitment to improving patient outcomes and tackling pressing health challenges, establishing its reputation as a significant player in…
Classification
- Sector
- Communication Services
- Industry
- Publishing
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 23-2 MARUYAMACHO, TOKYO, JAPAN
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer